Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Proceedings of the National Academy of Sciences of the United States of America - 14 Dec 2004

Wong S, McLaughlin J, Cheng D, Zhang C, Shokat K M, Witte O N

Abstract excerpt

Protein kinase inhibitors can be effective in treating selected cancers, but most suppress several kinases. Imatinib mesylate has been useful in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and B cell acute lymphoblastic leukemia through the inhibition of BCR-ABL tyrosine kinase activity. Imatinib mesylate has also been shown to inhibit KIT, ARG, and platelet-derived growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Myeloproliferative Disorders

Share to Phosphotyrosine

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 15505216
DOI: 10.1073/pnas.0407061101
PMCID: PMC524218

Genes

BCR
KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.PMID 15505216Read ↗

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.Semantic proximity Read ↗

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cellsSemantic proximity Read ↗

SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinibSemantic proximity Read ↗

AKT is a therapeutic target in myeloproliferative neoplasms.Semantic proximity Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.Semantic proximity Read ↗

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.Semantic proximity Read ↗

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.Semantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.